Lung cancer, the leading cause of cancer death, is divided into several histological subtypes with large differences in molecular alterations, clinical presentation, and patient outcome. By a combined clinical and molecular approach the current project focuses on improving the molecular understanding of lung cancer and translate research findings into a clinical diagnostic setting.
By characterization of the genomic, transcriptional, and DNA methylation landscape in lung cancer subgroups defined by histology and other clinicopathological factors in both own and public cohorts we search for new molecular subgroups of potential clinical relevance, additional targets for synergistic treatment, and a deepened understanding of the molecular pathogenesis.
To identify operable lung cancer patients with risk for metastatic relapse we search for new prognostic biomarkers based on analysis of genome-wide gene expression data and conventional protein marker validation based on analysis of primary tumor tissue. By analysis of patient specific alterations in circulating tumor DNA in blood samples we aim to establish blood-based assays for early detection of lung cancer, treatment monitoring, and early detection of relapse in the primary and advanced setting.